Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.45 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 4/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30669762 | 0.91 | WDR5 (0.44) | PDE4BWDR5EPHX2GPR119 | |
| SCHEMBL28782708 | 0.88 | HTR2A (0.38) | PDE4BPDE4DEPHX2 | |
| SCHEMBL29775402 | 0.88 | HTR2A (0.38) | PDE4BPDE4DEPHX2 | |
| SCHEMBL31358051 | 0.78 | ESR2 (0.39) | PDE4BWDR5PDE4DPDE4APDE4C | |
| SCHEMBL23326161 | 0.77 | HTR2A (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL30473751 | 0.75 | WDR5 (0.42) | WDR5EPHX2GPR119 | |
| SCHEMBL25430944 | 0.75 | WDR5 (0.42) | WDR5EPHX2GPR119 | |
| SCHEMBL15595098 | 0.73 | PDK4 (0.47) | PDE4BGPR119 | |
| SCHEMBL25276830 | 0.72 | DGAT2 (0.49) | GPR119 | |
| SCHEMBL18686588 | 0.70 | TBK1 (0.42) | PDE4BPDE4DPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761083-B | 5-HT for treating depression 2A Agonists | 罗福拉公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-114761083-A | 5-HT for the treatment of depression2AAgonists | 罗福拉公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | PDE4B 461/4885WDR5 2558/4885PDE4D 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.